SLRC — SLR Investment Corp.

Summary of SLRC Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Investment Income (NII): $0.33 per share, consistent with the previous quarter.
• Net Income: $0.15 per share.
• Net Asset Value (NAV): $18.00 per share, down from $18.16 in Q1 2026, primarily due to markdowns in two loans placed on non-accrual.
• Comprehensive Portfolio: $3.2 billion, with $471 million in new investments and $431 million in repayments during the quarter.
• Debt: $1.16 billion outstanding with a net debt-to-equity ratio of 1.16x, within the target range of 0.9x to 1.25x.
• Gross Investment Income: $48.8 million, slightly down from $49.3 million in the prior quarter.
• Quarterly Distribution: Declared at $0.31 per share, payable on September 25, 2026.

2. Strategic Updates and Business Highlights

• SLRC is focusing on specialty finance strategies, which accounted for nearly all originations in Q2.
• The company has a strong liquidity profile with over $900 million available for deployment.
• Increased activity in asset-based lending (ABL) with a focus on healthcare, where they have over 30 years of experience.
• The firm is actively hiring and expanding its ABL and life sciences teams to enhance origination capabilities.
• Formation of an AI committee to assess risks and opportunities related to AI in investment strategies.

3. Forward Guidance and Outlook

• SLRC expects continued strong originations in specialty finance, with a similar trend anticipated for Q3.
• The company is positioned to take advantage of market dislocations, particularly in the healthcare sector.
• Anticipates growth in net investment income over the next year through strategic initiatives and portfolio expansion.

4. Bad News, Challenges, or Points of Concern

• The decline in NAV was attributed to two loans placed on non-accrual, raising concerns about potential systemic issues, although management emphasized these are isolated cases.
• The company faces challenges in the cash flow lending market due to increased competition and a lack of new transactions among private equity firms.
• Concerns regarding the upcoming software maturity wall, with a significant portion of private debt exposure in the software sector potentially facing refinancing challenges.

5. Notable Q&A Insights

• Management indicated a willingness to increase leverage towards the higher end of their target range, reflecting confidence in their portfolio.
• There is optimism regarding the life sciences sector due to increased M&A activity and FDA approvals, which could enhance investment opportunities.
• The firm is seeing more opportunities from regional banks as they retreat from certain lending markets, particularly in ABL.
• AI is viewed as a tool to enhance efficiency rather than a competitive threat, with ongoing efforts to integrate AI into their operations for better collateral management.

Overall, SLRC's Q2 2026 performance reflects a stable financial position with a strategic focus on specialty finance and asset-based lending, while navigating challenges in the broader lending environment.